Cabozantinib Ups Survival in Advanced Liver Cancer
Roxanne Nelson, BSN, RN
July 05, 2018
The targeted agent cabozantinib (Cabometyx, Exelixis) could be a new treatment option for previously treated patients with advanced hepatocellular carcinoma (HCC), suggest results from a phase 3 trial.
As compared with placebo, treatment with cabozantinib resulted in longer overall survival and progression-free survival.
Median overall survival was 2.2 months longer for patients who received cabozantinib, and treatment was associated with a 56% reduction in the risk for progression or death.
The results were initially presented at the Gastrointestinal Cancers Symposium (GICS) 2018 and were reported by Medscape Medical News at that time. They have now been published in the New England Journal of Medicine.
Continue reading: https://www.medscape.com/viewarticle/898917
Free registration may be required
No comments:
Post a Comment